Galmed Pharmaceuticals develops therapeutics for inflammatory diseases, focusing on metabolic conditions and leveraging drug research and development.

Galmed Pharmaceuticals Ltd.

Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis.

COM:GALMEDPHARMA

Galmed Pharmaceuticals

1.44

−9.43%

0.10

Last Close

1.34

04/04 21:55

Market Cap

2.39M

Beta: -

Volume Today

49.54K

Avg: -

name

homepage url

country

employee count

sector

industry

Description

competitor of

Metrics